Petros Grivas, MD, PhD, on Urothelial Carcinoma Roundup: Expert Perspective

Posted: Wednesday, September 20, 2017

Petros Grivas, MD, PhD, of the Cleveland Clinic’s Taussig Cancer Institute, summarizes a session he chaired on urothelial cancer, with papers covering tumor mutation burden; nivolumab efficacy; and epithelial-mesenchymal transition, T-cell infiltration, and outcomes with nivolumab in this disease setting.